Patents by Inventor Hosung Min

Hosung Min has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides and related molecules that bind to TALL-1
    Patent number: 8507426
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ?ID?NO:?100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ?ID?NO:?104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ?ID?NO:?105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ?ID?NO:?106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ?ID?NO:?107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ?ID?NO:?109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: August 13, 2013
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2
    Publication number: 20130158234
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: March 30, 2012
    Publication date: June 20, 2013
    Applicant: Amgen Inc.
    Inventors: Jonathan Daniel OLINER, Hosung Min
  • Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
    Patent number: 8388976
    Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: March 5, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
  • POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR
    Publication number: 20120316318
    Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Application
    Filed: August 17, 2012
    Publication date: December 13, 2012
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: A-yeon CHO, Min-kyung KIM, Brian Hosung MIN, Jong-sang RYU
  • Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
    Patent number: 8268322
    Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: September 18, 2012
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
  • CARRIER IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20120195879
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: March 19, 2010
    Publication date: August 2, 2012
    Applicant: Amgen Inc.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas C. Boone, Frederick W. Jacobsen, HoSung Min, Jane Talvenheimo, Taruna Arora, George Doellgast, Janet Doellgast
  • SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2
    Publication number: 20120141499
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: January 12, 2012
    Publication date: June 7, 2012
    Inventors: Jonathan Daniel OLINER, Hosung Min
  • PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY
    Publication number: 20120129771
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Application
    Filed: February 1, 2012
    Publication date: May 24, 2012
    Applicant: AMGEN INC.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • MYOSTATIN BINDING AGENTS
    Publication number: 20120083442
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 5, 2012
    Applicant: AMGEN INC.
    Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
  • Specific binding agents of human angiopoietin-2
    Patent number: 8129331
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: March 6, 2012
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 8124724
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: February 28, 2012
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Method of increasing muscle mass by administering a myostatin binding agent
    Patent number: 8071538
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: December 6, 2011
    Inventors: Hq Han, Hosung Min, Thomas C. Boone
  • THROMBOPOIETIC COMPOUNDS
    Publication number: 20110275122
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Application
    Filed: July 19, 2011
    Publication date: November 10, 2011
    Applicant: AMGEN INC.
    Inventors: Hosung MIN, Kenneth W. WALKER, Colin V. GEGG, JR., Francesco GALIMI, Jeonghoon SUN, Mei-Mei TSAI
  • Peptides and Related Compounds Having Thrombopoietic Activity
    Publication number: 20110229472
    Abstract: The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.
    Type: Application
    Filed: December 22, 2010
    Publication date: September 22, 2011
    Applicant: Amgen Inc.
    Inventors: Hosung Min, Karen C. Sitney, Cynthia Hartley
  • POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR
    Publication number: 20110200622
    Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Application
    Filed: December 20, 2010
    Publication date: August 18, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: A-yeon CHO, Min-kyung KIM, Brian Hosung MIN, Jong-sang RYU
  • Thrombopoietic compounds
    Patent number: 7981425
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: July 19, 2011
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Kenneth W. Walker, Colin V. Gegg, Jr., Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
  • POLYPEPTIDES SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND METHODS THEREFOR
    Publication number: 20110158994
    Abstract: A polypeptide inhibiting binding between vascular endothelial growth factor receptor-2 and a vascular endothelial growth factor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Application
    Filed: December 20, 2010
    Publication date: June 30, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: A-yeon CHO, Min-kyung KIM, Brian Hosung MIN, Jong-sang RYU
  • Binding agents which inhibit myostatin
    Patent number: 7928075
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: April 19, 2011
    Assignee: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas C. Boone
  • ANTIBODY-PEPTIDE FUSED SYNERGIBODY
    Publication number: 20110076723
    Abstract: Disclosed herein are synergibodies, antibody-peptide fused protein molecules containing antibodies and bioactive peptides, which function in the occurrence or progress of the identical disease.
    Type: Application
    Filed: May 22, 2009
    Publication date: March 31, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Brian Hosung Min, Jong Sang Ryu
  • Myostatin binding agents
    Publication number: 20100330072
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 30, 2010
    Applicant: Amgen Inc.
    Inventors: HQ Han, Hosung Min, Thomas Charles Boone